Search Results - ningqiang+gong

4 Results Sort By:
Reducing The Adverse Side Effects Of Using Native T-Cells To Destroy Cancer Cells
A Switchable Bispecific T-Cell Nanoengager (sBiTNE) to link T cells with cancer cells that can be reversed if off-tumor toxicity is detected. Problem: Compounds which link native T-cells with the surface antigens found on cancer cells have emerged as an effective treatment for blood malignancies and are currently being developed for solid tumors....
Published: 4/16/2025   |   Inventor(s): Michael Mitchell, Ningqiang Gong
Keywords(s): Bioengineering, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology, Protein/Peptide (Non-Antibody), Small Molecule
Category(s): Technology Classifications > Therapeutics
Targeted, Enhanced Modification Of Lipid NanoparticlesTto Improve Tumor Therapeutic Efficacy
A method to inhibit small extracellular vesicles (sEVs) released by tumor cells to enhance lipid nanoparticle (LNP) accumulation in tumors. Problem: Lipid nanoparticles (LNPs) have shown promise as drug delivery systems for various diseases with several clinically approved products. However, their ability to deliver genes specifically to tumor cells...
Published: 4/11/2025   |   Inventor(s): Michael Mitchell, Ningqiang Gong, Wenqun Zhong, Wei Guo
Keywords(s): Bioengineering, Drug Delivery, Immunoncology, Oncology
Category(s): Technology Classifications > Therapeutics
Method to Alleviate Side Effects of CAR T Cell Immunotherapies
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity). Problem: CAR-T cell therapies lead to many adverse side effects such as cytokine release syndrome (CRS) and neurotoxicity. It has been shown that 20-70% of patients receiving...
Published: 12/20/2024   |   Inventor(s): Michael Mitchell, Ningqiang Gong
Keywords(s): Bioengineering, Cell Therapy, Immunology, Immunoncology, Immunotherapy, Oncology
Category(s): Technology Classifications > Chemical Processes and Synthesis, Technology Classifications > Therapeutics
Ionizable Lipid Nanoparticles with Low Immunogenicity Which Enable Repeated Administrations of mRNAs Encoding Gene Editors, Tumor Neoantigens, and Vaccine Payloads.
Using Mannich reaction-based combinatorial libraries to identify ionizable lipids for low-immunogenic and high-efficiency mRNA delivery. Problem: Lipid nanoparticle (LNP)-based delivery systems for mRNA-based therapeutics have recently demonstrated their clinical success in applications such as ONPATTRO® and the Pfizer/BioNTech and Moderna COVID-19...
Published: 10/1/2024   |   Inventor(s): Michael Mitchell, Ningqiang Gong
Keywords(s): Bioengineering, Drug Delivery
Category(s): Technology Classifications > Therapeutics